StockData
iBio, Inc. logo

iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.75+0.04 (+5.86%)

Close on Nov 17, 2026Market cap $48.11MP/E –Yield –

iBio price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

iBio's price to sales ratio was 459.1× on Nov 11, 2026, against 40.0× a year earlier. Over the last 5 years it ranged from 2.1× to 459.1×, with a median of 78.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026459.1×+380.9
2025Dec 31, 202578.2×−42.7
2024Dec 31, 2024120.9×+83.0
2023Dec 29, 202337.9×+35.8
2022Dec 30, 20222.1×−48.4
2021Dec 31, 202150.5×−47.1
2020Dec 31, 202097.6×+94.7
2019Dec 31, 20192.9×−34.6
2018Dec 31, 201837.5×−6.4
2017Dec 29, 201743.9×+5.2
2016Dec 30, 201638.6×+2.3
2015Dec 31, 201536.3×−9.1
2014Dec 31, 201445.5×+14.2
2013Dec 31, 201331.2×+9.2
2012Dec 31, 201222.0×−103.1
2011Oct 31, 2011125.1×–

More iBio figures

See a number that looks wrong?